Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Inhibition of heparin/protamine complex-induced complement activation by Compstatin in baboons.

A M Soulika1, M M Khan, T Hattori

  • 1Department of Pathology and Laboratory Medicine School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, 19104, USA.

Clinical Immunology (Orlando, Fla.)
|August 31, 2000
PubMed
Summary

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Lactoferrin and lysozyme for Kenyan children presenting with wasting and diarrhea: A 2 × 2 factorial randomized controlled trial.

medRxiv : the preprint server for health sciences·2026
Same author

Third Course of Radical Intent Conformal Radiation in Patients with Primary Brain Tumors.

Clinical oncology (Royal College of Radiologists (Great Britain))·2025
Same author

Neoadjuvant Chemotherapy in Locally Advanced Sinonasal Teratocarcinosarcoma a Rare Malignancy: An Audit From an Academic Tertiary Care Centre in India.

Clinical oncology (Royal College of Radiologists (Great Britain))·2024
Same author

Matrix-bound nanovesicle-associated IL-33 supports functional recovery after skeletal muscle injury by initiating a pro-regenerative macrophage phenotypic transition.

NPJ Regenerative medicine·2024
Same author

Search for Heavy Neutral Leptons in Decays of W Bosons Using a Dilepton Displaced Vertex in sqrt[s]=13  TeV pp Collisions with the ATLAS Detector.

Physical review letters·2023
Same author

Glioma radiogenomics and artificial intelligence: road to precision cancer medicine.

Clinical radiology·2022

Compstatin effectively prevented complement activation during cardiac surgery in baboons without adverse effects. This peptide inhibitor shows promise for clinical use and oral drug development.

Area of Science:

  • Immunology
  • Cardiovascular Surgery
  • Pharmacology

Background:

  • Complement activation is a key inflammatory response after cardiac surgery and cardiopulmonary bypass.
  • This activation contributes to postoperative organ dysfunction, fluid accumulation, and patient morbidity.
  • Heparin-protamine complexes formed during extracorporeal circulation trigger complement system activation.

Purpose of the Study:

  • To evaluate the efficacy of Compstatin, a novel peptide inhibitor, in preventing complement activation induced by heparin and protamine.
  • To assess the safety and effectiveness of Compstatin in a preclinical primate model relevant to human physiology.

Main Methods:

  • The study utilized baboons, chosen for Compstatin's binding to baboon C3 and resistance to proteolytic cleavage in their blood.

Related Experiment Videos

  • Various doses and administration regimens of Compstatin were tested to determine optimal inhibition.
  • Compstatin's effects on heparin/protamine-induced complement activation were measured in vivo, alongside hemodynamic parameters.

    • Main Results:

    • Compstatin achieved complete inhibition of complement activation at a total dose of 21 mg/kg, administered via bolus and infusion.
    • No adverse effects on heart rate or systemic, central venous, and pulmonary arterial pressures were observed.
    • The study demonstrated Compstatin's safety and efficacy in preventing complement activation in a relevant animal model.

    Conclusions:

    • Compstatin is a safe and effective complement inhibitor with potential for clinical application in cardiac surgery.
    • Compstatin can prevent complement activation during and after cardiopulmonary bypass procedures.
    • The findings support Compstatin as a prototype for developing orally administered complement-inhibiting drugs.